These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23305796)

  • 1. Molecular markers in pancreatic cancer diagnosis.
    Herreros-Villanueva M; Gironella M; Castells A; Bujanda L
    Clin Chim Acta; 2013 Mar; 418():22-9. PubMed ID: 23305796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.
    Fong ZV; Winter JM
    Cancer J; 2012; 18(6):530-8. PubMed ID: 23187839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
    Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
    Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
    Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
    Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of serum diagnosis of pancreatic cancer by using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
    Gao H; Zheng Z; Yue Z; Liu F; Zhou L; Zhao X
    Int J Mol Med; 2012 Nov; 30(5):1061-8. PubMed ID: 22941199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma.
    Park HD; Kang ES; Kim JW; Lee KT; Lee KH; Park YS; Park JO; Lee J; Heo JS; Choi SH; Choi DW; Kim S; Lee JK; Lee SY
    Proteomics; 2012 Dec; 12(23-24):3590-7. PubMed ID: 23065739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards pancreatic cancer diagnosis using EIS biochips.
    Chiriacò MS; Primiceri E; Monteduro AG; Bove A; Leporatti S; Capello M; Ferri-Borgogno S; Rinaldi R; Novelli F; Maruccio G
    Lab Chip; 2013 Feb; 13(4):730-4. PubMed ID: 23287869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel serum metabolomics-based diagnostic approach to pancreatic cancer.
    Kobayashi T; Nishiumi S; Ikeda A; Yoshie T; Sakai A; Matsubara A; Izumi Y; Tsumura H; Tsuda M; Nishisaki H; Hayashi N; Kawano S; Fujiwara Y; Minami H; Takenawa T; Azuma T; Yoshida M
    Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):571-9. PubMed ID: 23542803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational biomarkers for pancreatic adenocarcinoma: where do we stand?
    Datta J; Vollmer CM
    South Med J; 2014 Apr; 107(4):256-63. PubMed ID: 24937521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.
    Xue Y; Abou Tayoun AN; Abo KM; Pipas JM; Gordon SR; Gardner TB; Barth RJ; Suriawinata AA; Tsongalis GJ
    Cancer Genet; 2013 Jun; 206(6):217-21. PubMed ID: 23933230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.
    Lee MJ; Na K; Jeong SK; Lim JS; Kim SA; Lee MJ; Song SY; Kim H; Hancock WS; Paik YK
    J Proteome Res; 2014 Nov; 13(11):4878-88. PubMed ID: 25057901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward a better understanding of pancreatic ductal adenocarcinoma: glimmers of hope?
    Partensky C
    Pancreas; 2013 Jul; 42(5):729-39. PubMed ID: 23648843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of serum parameters panels for the early detection of pancreatic cancer.
    Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
    Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in proteomically subtyping pancreatic ductal adenocarcinomas and their potential clinical impact.
    Roesli C
    Expert Rev Proteomics; 2015 Feb; 12(1):5-8. PubMed ID: 25407217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylation profile of circulating plasma DNA in patients with pancreatic cancer.
    Melnikov AA; Scholtens D; Talamonti MS; Bentrem DJ; Levenson VV
    J Surg Oncol; 2009 Feb; 99(2):119-22. PubMed ID: 19065635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular markers of early pancreatic cancer.
    Goggins M
    J Clin Oncol; 2005 Jul; 23(20):4524-31. PubMed ID: 16002843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas.
    Fukamachi K; Tanaka H; Hagiwara Y; Ohara H; Joh T; Iigo M; Alexander DB; Xu J; Long N; Takigahira M; Yanagihara K; Hino O; Saito I; Tsuda H
    Biochem Biophys Res Commun; 2009 Dec; 390(3):636-41. PubMed ID: 19818733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment.
    Singh P; Srinivasan R; Wig JD
    Pancreas; 2011 Jul; 40(5):644-52. PubMed ID: 21673535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma.
    Szafranska-Schwarzbach AE; Adai AT; Lee LS; Conwell DL; Andruss BF
    Expert Rev Mol Diagn; 2011 Apr; 11(3):249-57. PubMed ID: 21463235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma.
    Uno K; Azuma T; Nakajima M; Yasuda K; Hayakumo T; Mukai H; Sakai T; Kawai K
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1333-8. PubMed ID: 11129230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.